AMT has developed Glybera for the treatment of patients who are suffering from genetic disorder lipoprotein lipase deficiency (LPLD).
The re-examination of the dossier is expected to be concluded by the end of 2011.
In a clinical trial, Glybera (alipogene tiparvovec) showed reduction in the the risk of pancreatitis in patients with LPLD.